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Abstract We have used confocal microscopy to elucidate the
e¡ects of antiandrogens on nuclear localization of the androgen
receptor (AR) with its transcriptional coactivator GRIP1. We
show that the agonist-activated AR recruits GRIP1 to colocal-
ize with the receptor in the nucleoplasm. By contrast, AR com-
plexed to the antiandrogens hydroxy£utamide and bicalutamide
fails to in£uence nuclear distribution of GRIP1. Likewise, the
non-steroidal antiandrogens prevent the agonist-induced AR^
GRIP1 colocalization from occurring. Androgen antagonists
a¡ect nuclear redistribution of AR^GRIP1 in a fashion that
parallels their e¡ects on the transcriptional activity of AR, in
that the pure antagonists block GRIP1-dependent activation of
AR function, whereas the mixed antagonist/agonist cyproterone
acetate promotes both AR-driven redistribution of GRIP1 and
activation of AR by GRIP1. + 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Androgens are critical for the development and the main-
tenance of male sexual characteristics and their action is medi-
ated through the androgen receptor (AR) [1] that belongs to
the steroid receptor subfamily of nuclear receptors [2]. Nu-
clear receptors regulate transcription of target genes in re-
sponse to binding to cognate ligands and consist of three
principal domains: a highly variable N-terminal transactiva-
tion domain (NTD), a conserved DNA-binding domain and a
somewhat more variable C-terminal ligand-binding domain
(LBD) [2]. The transcription activation functions (AF) 1 and
2 of nuclear receptors reside in the NTD and the LBD, re-
spectively. The AF2 of AR is very weak compared to other
steroid receptors [3^5]. In addition to harboring the strong
and hormone-independent AF1, the AR NTD contains con-
served FXXLF and WXXLF motifs that are important for
the interaction with hormone-occupied LBD [6^9]. The andro-
gen-dependent NTD/LBD interaction is probably direct, but
it can be enhanced by binding of coactivator proteins, such as
SRC-1 and GRIP1 (TIF2) [6,7]. These two related p160 co-
activators have distinct regions that interact with the NTD
and the LBD, thereby potentially bridging the NTD/LBD
interaction of AR [4,10,11]. The p160 proteins bind to AF2
regions of nuclear receptor LBDs via the LXXLL motifs (NR
boxes), whereas regions C-terminal to these motifs are in-
volved in the interaction with AF1 regions of some nuclear
receptors, such as AR [4,11,12]. The p160 coactivators are, in
turn, capable of recruiting histone acetyltransferases and
thereby remodeling chromatin structure, or as is the case
with SRC-1, the coactivator itself possesses acetyltransferase
activity [10]. These interactions have been shown to result in
augmentation of AR-dependent transcription [4,5,11,13^15].
Even though several aspects of the interplay between the
agonist-bound AR and its coactivator proteins have recently
become less elusive, very little is known of the ways by which
antiandrogens a¡ect subnuclear distribution of AR and dy-
namics of coactivator recruitment by AR. We and others have
previously shown that AR antagonists fail to induce a tran-
scriptionally competent conformation in the AR LBD in vi-
tro, but reverse the agonist-elicited conformational change in
the LBD [16,17]. In this work, we have visualized by confocal
microscopy the e¡ects of antiandrogens on the distribution of
AR and GRIP1 at a single cell level. Our results show that the
agonist-bound AR is involved in active recruitment of GRIP1
in the nucleoplasm. Furthermore, our assay clearly di¡eren-
tiates between pure agonists and mixed agonists/antagonists in
their ability to in£uence GRIP1 recruitment by AR.
2. Materials and methods
2.1. Materials
Chemicals were obtained from Sigma (St. Louis, MO, USA). Tes-
tosterone (T) was purchased from Makor Chemicals (Jerusalem, Isra-
el). Non-steroidal antiandrogen bicalutamide (BCA) [Casodex, (2RS)-
4P-cyano-3-(4-£uorophenylsulfonyl)-2-hydroxy-2-methyl-3P-(tri£uoro-
methyl) propionanilide] and hydroxy£utamide (OH-Flu) (4-hydroxy-
K,K,K-tri£uoro-2-methyl-4P-nitro-m-propionotoluidide) were gifts
from Zeneca Pharmaceuticals (Maccles¢eld, UK) and Schering
Corp. (Bloom¢eld, NJ, USA), respectively. Cyproterone acetate
(CPA) (6-chloro-1,2-methylene-17K-hydroxy-4,6-pregnadiene-3,20-di-
one-acetate) was from Schering AG (Berlin, Germany). All cell cul-
ture reagents were from Gibco Life Technologies (Grand Island, NY,
USA). Enhanced green £uorescent protein (EGFP)-AR, its mutants,
pSG5-hAR, and pPB(3285/+32)-LUC have been described [18,19].
pSG5-GRIP1 was a gift from Dr. Michael Stallcup (University of
Southern California, Los Angeles, CA, USA). pCMVL was from
Clonetech (Palo Alto, CA, USA).
2.2. Transactivation assays
COS-1 cells (from American Type Culture Collection, ATCC, Ma-
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nassas, VA, USA) were maintained in Dulbecco’s minimal essential
medium containing penicillin (25 U/ml), streptomycin (25 U/ml),
and 10% fetal bovine serum (FBS). LNCaP cells (ATCC) were cul-
tured in RPMI 1640 supplemented with penicillin (25 U/ml), strepto-
mycin (25 U/ml), 2 mM glutamine and 10% FBS. Transfections were
performed using FuGENE 6 reagent (Roche Molecular Biochemicals,
Mannheim, Germany) according to the manufacturer’s instructions.
In brief, 30U103 COS-1 cells were seeded on 12-well plates 24 h
before transfection. Four hours before transfection, the cells received
fresh medium containing 10% charcoal-stripped (CS) FBS, and were
transfected 200 ng of reporter plasmid, 20 ng of pCMVL and 20 ng of
pSG5-AR with or without 200 ng of pSG5-GRIP1. Eighteen hours
after transfection, the cells received fresh medium containing 2% CS
FBS with indicated concentrations of T and/or antiandrogen. After a
30-h culture, the cells were harvested, lysed in reporter lysis bu¡er
(Promega, Madison, WI, USA), and the luciferase (LUC) and L-ga-
lactosidase activities were assayed as described [9].
2.3. Microscopic inspection of AR and GRIP1 distribution
COS-1 cells grown on glass coverslips (155U103 cells/well) on 6-
well plates were transfected with FuGENE reagent with 750 ng of
EGFP-AR expression plasmid with or without pSG5-GRIP1, and
total DNA amount was balanced to 1.5 Wg with empty pSG5.
Twenty-four hours after transfection, the cells received fresh medium
with 2% CS FBS containing vehicle, T or antiandrogen for 24 h, after
which they were ¢xed with paraformaldehyde (4% in PBS) and per-
meabilized with Triton X-100 [18]. For hormone withdrawal experi-
ments, the cells received T for 8 h, after which the cultures were
washed four times with warm hormone-free medium and maintained
in this medium for additional 15 h until ¢xed. Immuno£uorescence
labeling was performed with Rhodamine-Red-X-conjugated anti-
mouse IgG (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) recognizing monoclonal mouse anti-GRIP1 (a generous
gift from Dr. Myles Brown, Dana-Farber Cancer Institute, Boston,
MA, USA). Fluorescence analysis was carried out with Bio-Rad
MRC-1024 confocal laser system (488 nm excitation for EGFP and
568 nm for rhodamine) connected to Zeiss Axiovert 135 M micro-
scope using a 63U, 1.4 numerical aperture oil immersion objective.
Both channels were excited and collected separately and merged for
the inspection of colocalization.
3. Results
3.1. Subcellular distribution of AR and GRIP1 and the e¡ect of
androgen
AR containing N-terminal fusion to EGFP and GRIP1
were expressed in COS-1 cells, and their subcellular distribu-
tion was examined by confocal laser microscopy. In the ab-
sence of androgen, AR resides both in the cytoplasm and the
nucleus (Fig. 1A). Exposure to 100 nM T brings about com-
plete nuclear transport of AR, and holo-AR shows a pattern
comprising hundreds of ¢ne nuclear granules that are distrib-
uted throughout the nucleus but excluded from the nucleoli
(Fig. 1B). A lower concentration of T (10 nM) elicits the same
e¡ect (see Fig. 3). EGFP-fusion part does not in£uence the
subcellular distribution or the amount of the receptor, since
non-tagged AR transfected into COS-1 cells, detected with
anti-AR antibody, forms similar small foci that are scattered
throughout the nucleoplasm but not in the nucleoli (data not
shown). Importantly, also endogenous AR in LNCaP cells
displays a nuclear distribution that is comparable to that of
EGFP-AR (Fig. 1G).
When transfected alone, GRIP1 localizes exclusively in nu-
clei and resides in round granules that are considerably larger
in size and fewer in number than the AR granules (Fig. 1C).
The distribution of the scarce nuclear apo-AR population is
distinct from that of GRIP1 (Fig. 1D). Interestingly, agonist-
occupied AR recruits GRIP1 to redistribute from tens of foci
to hundreds of small granules that now colocalize with AR
(Fig. 1E). Addition of T in the absence of AR does not in-
£uence of the distribution pattern of GRIP1 (data not
shown). Removal of androgen from the culture medium has
previously been shown to bring about export of AR to the
cytoplasm [18,21], and multiple rounds of nucleocytoplasmic
recycling of the receptor has been observed in COS-1 cells
under conditions of inhibited protein synthesis [21]. Androgen
withdrawal breaks down the colocalization of AR and GRIP1
and permits GRIP1 to return to its original distribution pat-
tern (cf. Fig. 1C,F). Thus, the formation of subnuclear com-
plexes containing colocalized AR and GRIP1 is a reversible
event that is dependent on receptor occupancy. However,
since protein synthesis was not inhibited in this experiment,
some of the observed molecules may also represent newly syn-
thesized ones.
Fig. 1. Holo-AR rearranges nuclear distribution of GRIP1 in COS-
1 cells. COS-1 cells grown on coverslips on 6-well plates were trans-
fected with expression vectors encoding pEGFP-AR or without
pSG5-GRIP1. After transfection, cells were cultured in 2% CS FBS
and exposed to 100 nM T for 24 h as indicated. For immuno£uo-
rescence of ¢xed cells, GRIP1 recognized by monoclonal anti-
GRIP1 antibody was detected with Rhodamine-Red-X-labeled sec-
ondary antibody. No staining was seen in the absence of the trans-
fected GRIP1 or the primary antibody (data not shown). Cells were
analyzed by using Bio-Rad MRC-1024 confocal laser scanning sys-
tem connected to a Zeiss Axiovert 135M microscope. Images were
collected separately for each channel (EGFP at 488 nm and rhod-
amine at 568 nm excitation) and merged as indicated. A,B: EGFP-
AR in the absence and in the presence of T, respectively. C: GRIP1
in the presence of T without cotransfected EGFP-AR. D,E: GRIP1
with cotransfected EGFP-AR in the absence and in the presence of
T, respectively. F: EGFP-AR and GRIP1 15 h after T removal. G:
Distribution of endogenous AR in LNCaP cells, as detected by us-
ing an AR-speci¢c antibody [20] and FITC-conjugated anti-rabbit
secondary antibody (Jackson ImmunoResearch Laboratories). The
LNCaP cells were treated with 100 nM T for 18 h prior to ¢xation.
Endogenous GRIP1 in LNCaP cells was not detectable with the
monoclonal anti-GRIP1 antibody.
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3.2. Antiandrogens modulate the activation of AR-dependent
transcription by GRIP1
To examine the e¡ect of di¡erent antiandrogens on the
activation of AR-dependent transcription by GRIP1, COS-1
cells were transfected with AR and GRIP1 expression vectors
together with a LUC reporter driven by the natural probasin
promoter [pPB(-285/+32)-LUC]. Exposure to T (10 nM) acti-
vates the reporter gene by s 10-fold, and ectopic expression
of GRIP1 increases AR-dependent transcription by V3-fold,
without in£uencing reporter gene activity in the absence of
androgen or AR (Fig. 2). The non-steroidal antiandrogens
BCA (1 WM) and OH-Flu (1 WM) are incapable of activating
transcription even in the presence of GRIP1, whereas in cells
supplemented with CPA (1 WM), GRIP1 increases AR-medi-
ated transcription by 4.5-fold. A 100-fold molar excess of OH-
Flu over T (1 WM vs. 10 nM) renders AR transcriptionally
inert without ectopic GRIP1 and abolishes v 90% of the re-
porter gene activity measured in the presence of GRIP1 (Fig.
2). BCA is somewhat less potent than OH-Flu in inhibiting
GRIP1-dependent activation of AR function. The mixed an-
tagonist/agonist CPA, in turn, fails to inhibit signi¢cantly the
function of agonist-bound AR under the same conditions
(Fig. 2).
3.3. Antiandrogens in£uence nuclear colocalization of AR with
GRIP1
To examine whether subnuclear localization of AR and
GRIP1 is reorganized by antiandrogens in a fashion that com-
plies with the transactivation events described above, EGFP-
AR was coexpressed with GRIP1 in COS-1 cells, and the
e¡ects of antiandrogens on their distribution were visualized.
Even though pure antagonists OH-Flu and BCA are known
to bring about translocation of AR from cytoplasm to nuclei
[18,22], AR complexed to these ligands fails to recruit GRIP1
in the nucleoplasm, as there is no redistribution of the coac-
Fig. 2. The pure antagonists OH-Flu and BCA, but not the partial
antagonist/agonist CPA, blunt the e¡ect of GRIP1 on AR-depen-
dent transcription. COS-1 cells grown on 12-well plates were trans-
fected with 20 ng of pSG5-AR, 20 ng of pCMVL, 160 ng of
pPB(3285/+32)-LUC with or without 200 ng of pSG5-GRIP1.
Twenty-four hours after transfection, the cells received 2% CS FBS
containing T (10 nM), OH-Flu (1 WM), BCA (1 WM) or CPA
(1 WM), as depicted by the + and 3 signs, and were cultured for
additional 24 h. LUC activities in the cell extracts were adjusted to
transfection e⁄ciency using L-galactosidase activity. The activity of
wild-type AR in the presence of 10 nM T is set as 100 and the
meanUS.E.M. values of three independent experiments with tripli-
cate samples are shown.
Fig. 3. Pure antiandrogens disrupt the colocalization of AR and
GRIP1 in the nucleoplasm. COS-1 cells grown on coverslips on 6-
well plates were transfected with 0.75 Wg of pEGFP-AR and 0.75
Wg of pSG5-GRIP1 expression plasmids. Twenty-four hours after
transfection, the cells received fresh medium containing 2% CS FBS
with (A) 10 nM T, (B) 1 WM OH-Flu, (C) 10 nM T with 1 WM
OH-Flu, (D) 1 WM BCA, (E) 10 nM T with 1 WM BCA, or (F)
1 WM CPA. After a 24-h incubation, the cells were ¢xed and
GRIP1-detected by using monoclonal anti-GRIP1 antibody that, in
turn, was recognized by Rhodamine-Red-X-conjugated secondary
antibody. Three-hour treatment with BCA or OH-Flu is su⁄cient
to break down the colocalization of holo-AR and GRIP1 (data not
shown). Cells were analyzed and images were captured separately
for EGFP and rhodamine as described in Fig. 1.
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tivator (Fig. 3B,D). Importantly, an excess of OH-Flu or
BCA e⁄ciently prevents T-induced redistribution of GRIP1
by AR in nuclei (Fig. 3C,E). Nuclear distribution of AR and
GRIP1 in the presence of CPA is comparable to that seen
with T, and CPA does not elicit any further redistribution
of AR or GRIP1 in the nucleoplasm when present together
with androgen (Fig. 3F and data not shown). In sum, anti-
androgens regulate nuclear redistribution of AR and GRIP1
in a fashion commensurate with their e¡ects on transactiva-
tion, in that only pure antiandrogens that abolish activation
of AR function by GRIP1 also prevent GRIP1 from colocal-
izing to the same nuclear foci as AR.
4. Discussion
We have used confocal laser microscopy to study the intra-
cellular dynamics of AR and its transcriptional coactivator
GRIP1. This study documents, for the ¢rst time, at a single
cell level that pure antiandrogens OH-Flu and BCA are able
to disrupt the colocalization of AR with GRIP1. The AR^
GRIP1 association in nuclei was shown to occur as an ago-
nist-induced recruitment of GRIP1 by AR, i.e. the nuclear
distribution of GRIP1 was rearranged from discrete round
foci to very ¢ne granular pattern colocalizing with AR.
Even though OH-Flu and BCA promoted nuclear transloca-
tion of the cytoplasmic AR, they did not permit AR^GRIP1
association to take place, but were capable of disrupting the
agonist-induced colocalization. By contrast, the partial ago-
nist/antagonist CPA promoted colocalization of AR and
GRIP1. These results are in line with the behavior of the
antihormones in transactivation assays; CPA elicited tran-
scriptionally productive AR^GRIP1 interaction, whereas
pure antagonists OH-Flu and BCA were not only inactive
in this respect but also capable of blocking the e¡ect of
GRIP1 on AR-dependent transcription.
Our results are reminiscent of the ligand-speci¢c recruit-
ment of £uorescent protein-fused GRIP1 to estrogen receptor
K (ERK)-containing subnuclear domains, in that estradiol and
the partial agonist hydroxytamoxifen, but not the pure antag-
onist ICI 182 780, elicited recruitment of GRIP1 [23]. Colo-
calization of coactivator SRC-1 with ERK to nuclear matrix-
bound foci has been similarly shown to occur in response to
estradiol but not to antagonists [24]. However, the behavior of
AR with p160 coactivator proteins cannot be inferred from
these ¢ndings, as many of the molecular features and inter-
actions of AR di¡er critically from those of ER [3^9]. While
this paper was ¢nalized for publication, Saitoh et al. reported
agonist-dependent colocalization of £uorescent protein
(YFP)-tagged TIF2 with AR in COS-7 cells [25], but the ef-
fects of antihormones on the colocalization were not ad-
dressed in their study. In contrast to the untagged GRIP1
used in this work, the YFP-TIF2 showed a di¡use nuclear
distribution pattern when expressed alone or with apo-AR.
The £uorescent protein tag in TIF2 may in£uence the nuclear
distribution of the protein and thus, at least in part, explain
this di¡erence.
Nuclear organization appears to provide the architectural
framework for the control of transcription [26]. Active tran-
scription has been demonstrated to occur at numerous spa-
tially distinct foci that are associated with the nuclear matrix.
Nuclear organization is dynamic [27], and also steroid recep-
tors are continuously attaching to and detaching from the
chromatin [28,29]. As shown in the present and two recent
studies [21,30], transcriptionally active agonist-occupied AR
localizes into a large number (typically 250^400) of nuclear
foci that, according to Tomura et al. [30], reside in the bound-
ary region between euchromatin and heterochromatin. The
nuclear substructures to which AR and GRIP1 localize are
largely unknown, although AR has been shown to be attached
to the nuclear matrix [18,21,31], and a granular subpopulation
of GRIP1 has been proposed to associate with the ND10
nuclear domains (promyelocytic leukemia (PML) bodies)
[32]. The latter domains appear to contain several proteins,
including PML gene product and the CREB-binding protein.
AR does not colocalize with PML, but interestingly, RNA
polymerase II is distributed to hundreds of small foci re-
sembling the holo-AR-containing speckles (our unpublished
results), and it is conceivable that these foci represent ‘mat-
uration’ sites for transcriptionally competent holo-AR-
coactivator complexes.
Despite the fact that antiandrogens have been under intense
investigation, the exact molecular mechanism of their action
and especially the individual steps in AR signaling that they
perturb have remained elusive. Many di¡erent steps in AR
function ^ from transactivation to AR mRNA and protein
stability, nucleocytoplasmic tra⁄cking, homodimerization,
DNA binding, and receptor phosphorylation ^ are targeted
by antiandrogens [18,20,22,33,34]. The physiological role of
nuclear receptor corepressors in the function of various anti-
androgens is currently unclear. Recently, Dotzlaw et al. [35]
detected binding of SMRT to AR complexed with CPA, but
not in the presence of BCA or OF-Flu, whereas according to
Shang et al. [36], BCA-bound AR indeed recruits both SMRT
and N-CoR. However, we have been unable to detect CPA-,
BCA- or OH-Flu-induced interaction between AR (fused to
Gal4 DNA-binding domain) and SMRT (fused to VP16 acti-
vation domain) in COS-1 cells by using two-hybrid assays
(our unpublished results).
Even though the nuclear distribution pattern of endogenous
GRIP1 may di¡er from that of the transfected protein, our
¢ndings indicate clearly that the pure antiandrogens OH-Flu
and BCA, but not the partial agonist/antagonist CPA, can
attenuate AR function by releasing GRIP1 ^ probably the
related p160 nuclear receptor coactivators as well ^ from the
receptor-containing subnuclear sites. These data have impor-
tant implications in the development of next generation AR
antagonists and novel therapeutic modalities for recurrent
prostate cancer in which GRIP1 is often overexpressed [37].
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